author-photo

Hanne Hawle

20

Papers

224

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy

2020 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (9)
Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy

2019 Radiation Oncology
Show All
- Source
- Cite
- Save
Citations (14)
Incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosumab: Data from a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every four weeks (q4w) versus every 12 weeks (q12w)—SAKK 96/12 (REDUSE).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

2019 Blood
Show All
- Source
- Cite
- Save
Citations (29)
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

2018 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (30)
Intergroup phase III trial of neo-adjuvant chemotherapy, followed by chemoradiation and surgery with and without cetuximab in locally advanced esophageal carcinoma: First results from the SAKK 75/08 trial.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients

2017 Endocrine connections
Show All
- Source
- Cite
- Save
Citations (6)
Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

2016 Blood
Show All
- Source
- Cite
- Save
Citations (5)
The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

2016 Blood
Show All
- Source
- Cite
- Save
Citations (11)
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo- controlled double-blind phase II trial, SAKK 21/08

2015 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (27)